

[Aztreonam](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.3. Reserve group antibiotics](#)

Codes ATC: [J01DF01](#)

EMLc

Indication

Other specified bacterial diseases Code ICD11: [1C4Y](#)

INN

Aztreonam

Type de médicament

Chemical agent

Groupes d'antibiotiques

[RESERVE](#)

Type de liste

Liste complémentaire

Formulations

Parenteral > General injections > unspecified: 1 g in vial powder for injection ; 2 g in vial powder for injection

Historique des statuts LME

Ajouté pour la première fois en 2017 ([TRS 1006](#))

Retiré en 2019 ([TRS 1021](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Lire la suite [sur les brevets.](#)

Wikipédia

[Aztreonam](#)

DrugBank

[Aztreonam](#)

Résumé des preuves et recommandation du comité d'experts

With regard to the EML listing of antibiotics, the Committee endorsed revised criteria for the inclusion of Reserve group antibiotics on the Model List. Namely, Reserve group antibiotics should be included individually on the Model List when they have a favourable benefit-risk profile and proven activity against “Critical Priority” or “High Priority” pathogens as identified by the WHO Priority Pathogens List, most notably carbapenem resistant Enterobacteriaceae. Subsequently, the Committee recommended the removal of aztreonam, fourth- and fifth-generation cephalosporins (as classes), tigecycline and daptomycin from the EML and EMLc as these antibiotics did not meet the revised criteria for inclusion on the Model Lists as individual Reserve group agents.